DKTK

Colon cancer: Different Wnt signaling pathways lead colon cells astray

Signaling molecules in the Wnt family are some of the most essential messengers for continuous regeneration of our stressed colon mucosa. At the same time, "too much" Wnt is a frequent trigger for colon cancer. Wnt is therefore regarded as an important biomarker and treatment target. The cellular response triggered by Wnt can indicate positive or negative disease progression in colon cancer patients. Scientists from the German Cancer Consortium (DKTK) and Goethe University Frankfurt working at Georg Speyer House demonstrated this in a recent study.

Deadline 15 March 2019

Are you considering a career as a clinician scientist?

Apply for one of five available prestigious two-year DKFZ Clinician Scientist Fellowships! More information here.

We are asking for your support

Your Donation for Cancer Research
1st German Cancer Research Congress

Cancer research in Germany joins forces

At the 1st German Cancer Research Congress, taking place on February 4 and 5 in Heidelberg, around 500 participants meet to exchange knowledge and ideas about what excellent research in Germany can contribute to the fight against the widespread disease of cancer. Anja Karliczek, Federal Minister of Education and Research, and Theresia Bauer, State Minister of Science, Research and the Arts, participated in the opening event on World Cancer Day.

Latest News

The development of brain stem cells into new nerve cells and why this can lead to cancer

Stem cells are true "Jacks-of-all-trades" of our bodies, as they can turn into the many different cell types of all organs. This allows the tissues such as muscle or even brain to renew and to heal after injury. This amazing "multipotency" makes stem cells in the adult body key tools for the future of regenerative medicine. Scientists at the German Cancer Research Center (DKFZ) now publish in the journal "Nature" how brain stem cells make the decision to transform into new nerve cells.

Hopp Children's Cancer Center Heidelberg

ERC grant for Stefan Pfister: “We must further advance pediatric cancer research”

KiTZ director Stefan Pfister, professor of pediatric neurooncology at the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital, succeeded in gaining one of the prestigious ERC Consolidator Grants for his project entitled "BRAIN-MATCH". The goal of BRAIN-MATCH is to characterize normal brain development using molecular-biological methods and to compare it with the development of brain cancer. Pfister and his team plan to use the results obtained as a basis for finding new approaches in the treatment of brain cancer in children. The European Research Council (ERC) awards "Consolidator Grants" to support excellent scientists who are expanding their research activities.

Information


Search for research topic

Latest News

A major step towards digital oncology

New AI infrastructure for cancer research facilitates more complex mathematical models

Vaccination as a therapy

Experimental vaccine against cervical cancer successfully tested in mice

Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists' goal is to develop a therapeutic vaccine for people who are already suffering from cancer or cancer precursors and, thus, no longer benefit from preventive vaccination.

"Life Time"

European research for a healthier future

Our body's cells are constantly changing. But which of these changes are healthy developments and which lead to serious diseases? This is what LifeTime, a new transnational and interdisciplinary initiative of leading European researchers, aims to discover. The consortium is jointly coordinated by the Max Delbrück Center in Berlin and the Institut Curie in Paris, with the Helmholtz Association and the CNRS. Scientists from the DKFZ are also involved in the consortium. Life Time has now cleared an important hurdle: The consortium will be given one million euros and one year to develop a plan to embed its vision for a healthier future within the European research and innovation landscape.

DKFZ - A Video

to top